Analysts bullish on this largecap pharma stock after Q1 earnings; see up to 20.66% upside

Torrent Pharmaceuticals on Monday reported a strong performance for the first quarter of FY2025-26, with a 20 per cent year-on-year jump in consolidated net profit to Rs 548 crore. The growth was driven by solid sales across key markets, including India, the US, Brazil, and Germany. After the earnings, now what should investors do with the largecap firm's stock?

(This story will be updated shortly.)